Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding

Emerging coronaviruses: Genome structure, replication, and pathogenesis

(2020) Yu Chen et al.   JOURNAL OF MEDICAL VIROLOGY

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

(2020) Vanessa Monteil et al.   CELL

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

(2020) Wanbo Tai et al.   Cellular & Molecular Immunology

Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor

(2020) Xiangyu Chen et al.   Cellular & Molecular Immunology

The Role of Antibody Testing for SARS-CoV-2: Is There One?

(2020) Elitza S. Theel et al.   JOURNAL OF CLINICAL MICROBIOLOGY

A serological assay to detect SARS-CoV-2 seroconversion in humans

(2020) Fatima Amanat et al.   NATURE MEDICINE

A human monoclonal antibody blocking SARS-CoV-2 infection

(2020) Chunyan Wang et al.   Nature Communications

Assay Techniques and Test Development for COVID-19 Diagnosis

(2020) Linda J. Carter et al.   ACS Central Science

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

(2020) Davide F. Robbiani et al.   NATURE

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction

(2020) Chee Wah Tan et al.   NATURE BIOTECHNOLOGY

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

(2020) Takuya Sekine et al.   CELL

Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology

(2010) Jody D. Berry et al.   mAbs